Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

NCT07272499 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Orelabrutinib
DRUG: Rituximab (R)
DRUG: Lisaftoclax (APG-2575)
DRUG: Lisaftoclax (APG-2575)

Sponsor

Ruijin Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]